Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

IMPORTANCE: The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Oncol
Asıl Yazarlar: Abida, Wassim, Cheng, Michael L., Armenia, Joshua, Middha, Sumit, Autio, Karen A., Vargas, Hebert Alberto, Rathkopf, Dana, Morris, Michael J., Danila, Daniel C., Slovin, Susan F., Carbone, Emily, Barnett, Ethan S., Hullings, Melanie, Hechtman, Jaclyn F., Zehir, Ahmet, Shia, Jinru, Jonsson, Philip, Stadler, Zsofia K., Srinivasan, Preethi, Laudone, Vincent P., Reuter, Victor, Wolchok, Jedd D., Socci, Nicholas D., Taylor, Barry S., Berger, Michael F., Kantoff, Philip W., Sawyers, Charles L., Schultz, Nikolaus, Solit, David B., Gopalan, Anuradha, Scher, Howard I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2018
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459218/
https://ncbi.nlm.nih.gov/pubmed/30589920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5801
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller